RecruitingNCT07298083
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Sponsor
M.D. Anderson Cancer Center
Enrollment
60 participants
Start Date
Apr 2, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
Eligibility
Min Age: 1 Year
Inclusion Criteria6
- This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care.
- Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age < 18 years, both parents' signatures will be requested.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
- Recurrent or primary disease.
- Patients who are > 18 years should have the ability to understand and the willingness to sign a written informed consent document.
- English and non-English speaking patients.
Exclusion Criteria3
- Adult patients with cognitive impairment requiring a legally authorized representative for consent.
- Patients under age 1 and neonates.
- Patients who are pregnant and undergoing surgery for MPNST are not eligible.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07298083